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Abstract
Background: The choroid plexuses are the interface between the blood and the cerebrospinal fluid (CSF)
contained within the ventricular spaces of the central nervous system. The tight junctions linking adjacent cells of
the choroidal epithelium create a physical barrier to paracellular movement of molecules. Multispecific efflux
transporters as well as drug-metabolizing and antioxidant enzymes functioning in these cells contribute to a
metabolic barrier. These barrier properties reflect a neuroprotective function of the choroid plexus. The choroid
plexuses develop early during embryogenesis and provide pivotal control of the internal environment throughout
development when the brain is especially vulnerable to toxic insults. Perinatal injuries like hypoxia and trauma, and
exposure to drugs or toxic xenobiotics can have serious consequences on neurogenesis and long-term
development. The present study describes the developmental expression pattern of genes involved in the
neuroprotective functions of the blood–CSF barrier.
Methods: The transcriptome of rat lateral ventricular choroid plexuses isolated from fifteen-day-old embryos,
nineteen-day old fetuses, two-day old pups, and adults was analyzed by a combination of Affymetrix microarrays,
Illumina RNA-Sequencing, and quantitative RT-PCR.
Results: Genes coding for proteins involved in junction formation are expressed early during development. Overall
perinatal expression levels of genes involved in drug metabolism and antioxidant mechanisms are similar to, or
higher than levels measured in adults. A similar developmental pattern was observed for multispecific efflux
transporter genes of the Abc and Slc superfamilies. Expression of all these genes was more variable in choroid
plexus from fifteen-day-old embryos. A large panel of transcription factors involved in the xenobiotic- or cell stress-
mediated induction of detoxifying enzymes and transporters is also expressed throughout development.
Conclusions: This transcriptomic analysis suggests relatively well–established neuroprotective mechanisms at the
blood-CSF barrier throughout development of the rat. The expression of many transcription factors early in
development raises the possibility of additional protection for the vulnerable developing brain, should the fetus or
newborn be exposed to drugs or other xenobiotics.
Keywords: Cerebrospinal fluid, Development, Efflux transporter, Multidrug resistance, Detoxification, Drug
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Background
Choroid plexuses form the main interface between the
blood and cerebrospinal fluid (CSF) and participate in
the control of brain homeostasis. In the rat, choroid
plexuses of the fourth, lateral, and third ventricles ap-
pear in embryos on day 12, 13 and 16, respectively [1].
In human, choroid plexuses develop around week 6–7 of
gestation [2]. Selective influx transport and secretion
mechanisms confer on the choroidal epithelium an im-
portant role in supply of nutrient and bioactive mole-
cules to the developing brain [3,4]. The choroid plexuses
also produce and secrete most of the CSF through the
combined activity of various enzymes, transporters and
ion channels located in the epithelial cells [5]. The rate
of CSF secretion increases around birth in most mam-
mals [6,7].
In addition to these secreting and supplying activities,
the choroid plexuses fulfill neuroprotective functions
both as a physical and as a biochemical barrier between
the blood and the nascent CSF [8] (Figure 1). Transmis-
sion electron microscopy combined with the use of
electron–dense tracers [9] and freeze–fracture electron
microscopy [10,11] demonstrated that the tight junctions
(TJ), which link adjacent epithelial cells, constitute the
anatomical basis of this barrier. This physical barrier ap-
pears efficient in preventing the paracellular leakage of
low molecular weight molecules from the earliest stages
of plexus development [12-14]. The molecular compos-
ition of choroidal TJs is regulated during development,
as exemplified by the coordinated up– or down–regula-
tion of specific pore–forming and tightening claudins
that make up the core of the junctional complex [15]. In
addition to this physical barrier, a number of antioxidant
and drug metabolizing enzymes, and a wide variety
of multispecific efflux transporters participate in the
neuroprotective and detoxifying functions (Figure 1,
Table 1). Efflux transporters eliminate endogenous bio-
active metabolites and xenobiotics from the CSF or pre-
vent their entry through the choroidal epithelium. They
include primary energy-dependent unidirectional trans-
port pumps of the ATP-binding cassette (ABC) trans-
porter superfamily such as Abcc1 a and Abcc4 [16,17],
as well as multispecific transporters of the solute carrier
(Slc) family, such as Slco1a5, Slc22a8 [18,19], or Slc15a2
[20]. Activities of the antioxidant enzymes epoxide
hydrolases and glutathione peroxidases, and of drug-
conjugating enzymes are high in the choroid plexuses
[21]. Conjugation to glutathione or glucuronic acid,
coupled with a basolateral efflux of the produced metab-
olites, forms an efficient enzymatic barrier to the entry
of conjugating enzyme substrates into the CSF [22,23].
The molecular identification of all transporters and
drug metabolizing enzymes in the choroid plexus fulfill-
ing a biochemical barrier function at the interface be-
tween blood and CSF remains incomplete. Data on the
developmental expression pattern of these genes are
even scarcer. Abcc1, Abcc4 and Abcg2 transcripts are
detected in rat choroid plexuses as early as embryonic
Figure 1 Schematic representation of neuroprotective mechanisms at the blood-CSF barrier. In addition to tight junctions (red) that
prevent non-specific paracellular diffusion, a wide variety of multispecific efflux transporters (green), as well as antioxidant and drug metabolizing
enzymes (blue), participate in the neuroprotective and detoxifying functions of the choroid plexus. Only the most documented mechanisms are
represented on the scheme (see text for details and Table 1 for a description of enzyme and transporter families).
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Table 1 List of gene official symbols and aliases
Gene-symbol Aliases mRNA ID
ABC transporters
Abcb1b Mdr1, Pgy1, Abcb1 NM_012623
Abcc1 Mrp1 NM_022281
Abcc3 Mlp2, Mrp3 NM_080581
Abcc4 Mrp4 NM_133411
Abcc5 Mrp5, Abcc5a NM_053924
Abcc9 Sur2 NM_013040
Abcc10 Mrp7 NM_001108201
Abcg2 BCRP1 NM_181381
Solute carriers: organic anion transporting polypeptides
Slco2a1 Slc21a2, Matr1 NM_022667
Slco1a3 Slc21a4 NM_030837
Slco1a4 Slc21a5, Oatp2 NM_131906
Slco1a5 Slc21a7, Oatp3 NM_030838
Slco2b1 Slc21a9, moat1 NM_080786
Slco3a1 Slc21a11, Oatp3a1 NM_177481
Slco1c1 Bsat1, Slc21a14, Oatp14 NM_053441
Solute carriers: organic anion /cation/zwitterion transporters
Slc22a2 OCT2 NM_031584
Slc22a4 Octn1 NM_022270
Slc22a5 Octn2, CT1, UST2r NM_019269
Slc22a6 Oat1, Paht, Roat, Orctl1 NM_017224
Slc22a7 Oat2 NM_053537
Slc22a8 Oat3, Roct NM_031332
Slc22a12 Rst NM_001034943
Slc22a15 NM_001107707
Slc22a17 Boct, 24p3R NM_177421
Slc22a25 Ust1, Slc22a9 NM_138908
Solute carriers: nucleoside and peptide transporters
Slc15a2 Pept2 NM_031672
Slc28a2 Cnt2 NM_031664
Slc28a3 Cnt3 NM_080908
Slc29a1 Ent1 NM_031684
Slc29a2 Ent2 NM_031738
Slc29a3 Ent3 NM_181639
Slc29a4 NM_001105911
Cytochrome P450s, epoxide hydrolases, flavin-containing
monooxygenases
Cyp1b1 NM_012940
Cyp2d4 Cyp2d6, Cyp2d18 Cyp2d22 NM_138515
Cyp2j4 CYP2J2 NM_023025
Cyp2u1 NM_001024779
Ephx1, transcript
variant 1
MEH8 NM_001034090
Table 1 List of gene official symbols and aliases
(Continued)
Ephx1, transcript
variant 2
NM_012844
Ephx2 CEH, SEH NM_022936
Fmo1 RFMO1A NM_012792
Fmo2 NM_144737
Fmo3 NM_053433
Fmo4, transcript
variant 1
NM_144562
Fmo4, transcript
variant 2
NM_144561
Fmo5 NM_144739
UDP-glucuronosyltransferases and sulfotransferases transferases
Ugt1a1 UDPGT 1-1 NM_012683
Ugt1a2 UDPGT 1-2 NM_201423
Ugt1a3 UDPGT 1-3 NM_201424
Ugt1a5 UDPGT 1-5 NM_001039549
Ugt1a6 UDPGT 1-6 NM_057105
Ugt1a7c UDPGT 1-7 NM_130407
Ugt1a8 UDPGT 1-8 NM_175846
Ugt1a9 NM_201425
Ugt2a1 Ugt2a1p NM_022228
Sult1a1 Stm, Stp1, ASTIV, Mx-ST, PST-1 NM_031834
Sut1d1 Sultn, Sult-n NM_021769
Sult5a1 NM_001106194
Glutathione S-transferases (GSTs) and glutathione-synthesis related
genes
Gsta1 NM_017013
Gsta2 LOC494499
Gsta3 Yc1 NM_031509
Gsta4 NM_001106840
Gstm1 NM_017014
Gstm2 NM_177426
Gstm3 GstYb4 NM_020540
Gstm4 NM_001024304
Gstm5 NM_172038
Gstm7 NM_031154
Gstp1 Gst3, Gstp, Gstp2 NM_012577
Mgst1 NM_134349
Mgst2 NM_001106430
Mgst3 NM_001191594
Gss NM_012962
Gclc Glclc NM_012815
Gclm Glclr NM_017305
Heme oxygenases, biliverdin reductase
Hmox1 Ho1, Heox, Hmox, Ho-1, HEOXG NM_012580
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day 15. Abcg2 expression is highest at this stage and sub-
sequently declines in the adult [24]. The Abcc1 gene is
well expressed and its protein product already localized
at the basolateral blood–facing membrane of the chor-
oidal epithelium in both newborn rats [24,25], and
human neonates [26]. The enzymatic activity of the
sulfotransferase Sult1a1, which conjugates phenolic
drugs with sulfate, is high in human fetal choroid plex-
uses [27]. High glutathione-S-transferase (GST) activity
is detected in choroid plexuses of newborn rats and hu-
man fetuses [23]. These currently available data on chor-
oidal transport and detoxification activities at embryonic
and perinatal stages suggest that a functional biochem-
ical barrier supported by various enzymatic pathways
could contribute substantially to the protection of the
developing brain.
The central nervous system is especially vulnerable to
perinatal injuries, including hypoxia, systemic inflamma-
tion and traumatic brain injury. Maternal exposure to
neurotoxic compounds and drugs can have dramatic
consequences for neurogenesis, leading to irreparable
long-term neurodevelopmental disorders [28]. The
purpose of the present study was to expand our know-
ledge of neuroprotective mechanisms at the blood-CSF
barrier in the developing brain and our understanding of
the factors setting the cerebral bioavailability of drugs in
the context of pediatric treatments. We have established
the developmental expression profiles of genes involved
in drug transport and detoxification in the choroidal tis-
sue. We have combined data obtained from Illumina
RNA-Seq (high throughput RNA sequencing) and Af-
fymetrix microarray technologies developed in two inde-
pendent laboratories and analyzed by quantitative real-
time PCR (qRT-PCR) additional transcripts not repre-
sented on the array. The genes included in the analysis
were selected for their involvement in drug/xenobiotic
transport or in detoxification pathways. The transcription
of some of these genes is known to be regulated in periph-
eral organs under various physiological and pathological
Table 1 List of gene official symbols and aliases
(Continued)
Hmox2 Ho-2 NM_024387
Hmox3 HO-3 AF058787
Blvra NM_053850
Blvrb NM_001106236
Glutathione peroxidases and –reductase
Gpx1 GSHPx, GSHPx-1 NM_030826
Gpx3 Gpxp, GPx-P, GSHPx-3, GSHPx-P NM_022525
Gpx4 Phgpx, gpx-4, snGpx NM_017165
Gpx7 NM_001106673
Gpx8 NM_001106411
Gsr NM_053906
Sod1 CuZnSOD NM_017050
Sod2 NM_017051
Sod3 NM_012880
Cat CS1, Cas1,Catl, Cs-1, Cat01 NM_012520
Regulatory transcription factors
Nr1i2 PXR NM_052980
Nr1i3 CAR NM_022941
Rxra NM_012805
Ppara Nr1c1, Ppar NM_013196
Nr3c1 GR, Grc, Grl NM_012576
Cebpb LAP, TCF5, Il6dbp, NF-IL6 NM_024125
Ahr AhR NM_013149
Arnt Arnt1 NM_012780
Nfe2l2 Nrf2 NM_031789
Hif1a MOP1 NM_024359
Tp53 p53, Trp53 NM_030989
Monoamine oxidases, dopa decarboxylase, catechol-O
-methyltransferase
Maoa Mao NM_033653
Maob NM_013198
Ddc NM_012545
Comt NM_012531
Tight junction-associated genes
Cldn1 NM_031699
Cldn2 NM_001106846
Cldn3 NM_031700
Cldn6 NM_001102364
Cldn9 NM_001011889
Cldn10 NM_001106058
Cldn11 NM_053457
Cldn12 NM_001100813
Cldn19 NM_001008514
Cldn22 NM_001110143
Table 1 List of gene official symbols and aliases
(Continued)
Marveld1 Mrvldc1 NM_001107590
Marveld2 Mrvldc2, Tric NM_001108936
Marveld3 NM_001109132
Ocln NM_031329
Lsr Lisch7 NM_032616
Tjp1 ZO-1 NM_001106266
Tjp2 ZO-2 NM_053773
Tjp3 ZO-3 NM_001108073
F11r Jam1 NM_053796
Jam2 NM_001034004
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stimuli, and can also be pharmacologically modulated
[29-31]. For this reason, transcription factors involved in
the regulation of drug metabolizing enzymes and trans-
porters were included in this study.
Materials and methods
Tissue collection and RNA extraction
Animal care and procedures were conducted according
to the guidelines approved by the French ethical com-
mittee (decree 87–848), by the European Community
(directive 86-609-EEC) and the University of Melbourne
Animal Ethics Committee based on National Health and
Medical Research Council guidelines. Sprague–Dawley
rats, either adult males, pregnant time-dated females, or
females with their litter, were obtained from Janvier (Le
Genest Saint Isle, France) or the Biomedical Research Fa-
cility at the University of Melbourne (Victoria, Australia).
All animals were kept under similar conditions in
standard cages, with free access to food and tap water
under a controlled environment (12 h day/light cycles).
Choroid plexuses of the lateral ventricle were dissected
under a stereomicroscope from two-day-old (P2) and
adult rats as previously described and illustrated
[3,22,32]. Timed-pregnant female rats were anesthe-
tized with inhaled isoflurane and body temperature
maintained with a heated pad. Fifteen-day-old (E15)
embryos and nineteen-day-old (E19) fetuses were re-
moved one by one from the mother and used for brain
sampling and microdissection of the choroid plexuses
[33]. All steps were performed under RNAse-free con-
ditions. The collected tissues were snap-frozen in liquid
nitrogen and kept at −80°C until use.
For Affymetrix microarrays, choroid plexuses were
pooled from 3 (adult) or 5 (developing) animals. Total
RNA was isolated from two pools of choroid plexuses
sampled from E19, P2, or adult rats using the RNeasy®
Micro Kit (Qiagen, Valencia, CA, USA), and DNAse-
treated according to the manufacturer’s protocol. qRT-
PCR analysis was performed on four (P2, adult) or three
(embryonic) pools of mRNA. For Illumina RNA-Seq,
three pooled samples of ten lateral ventricular choroid
plexuses from each E15 and adult age were used. Total
RNA was extracted using the RNeasy Plus Mini Kit,
Qiashredder columns and gDNA removal columns
(Qiagen, Valencia, CA, USA) according to standard sup-
plier protocols. All RNA samples were quantified using a
NanoDrop 2000c spectrophotometer (Thermo Scientific,
Wilmington, DE, USA) and quality checked with the
Agilent 2100 Bioanalyser (Agilent Technologies, Palo
Alto, CA, USA).
Affymetrix microarray
Microarray analysis was performed using a high-density
oligonucleotide array (GeneChip Rat Genome 230 2.0
array, Affymetrix, Santa Clara, CA, USA). Total RNA
(100 ng) was amplified and biotin-labeled using
GeneChip® 3’ IVT Express target labeling and control re-
agents according to Affymetrix protocol (http://www.
affymetrix.com). Before amplification, all samples were
spiked with synthetic mRNAs at different concentra-
tions, which were used as positive controls to ascertain
the quality of the process. Biotinylated antisense cRNA
for microarray hybridization was prepared. After
final purification using magnetic beads, cRNAs were
quantified using a NanoDrop and quality checked with
Agilent 2100 Bioanalyzer. Hybridization was performed
according to the Affymetrix protocol. Briefly, 10 μg of
labelled cRNA was fragmented and denaturated in
hybridization buffer, then hybridized on the chip for 6 h
at 45°C with constant mixing by rotation at 60 rpm in
an Genechip hybridization oven 640 (Affymetrix).
After hybridization, arrays were washed and stained with
streptavidin-phycoerythrin (GeneChip® Hybridization Wash
and Stain Kit) in a fluidic 450 (Affymetrix) according to the
manufacturer’s instruction. The arrays were read with a
confocal laser (Genechip scanner 3000, Affymetrix). CEL
files summarizing the probe cell intensity data were gener-
ated using the Affymetrix GeneChip Command Console
software 3.0. Data were normalized with Affymetrix
Expression Console software using MAS5 statistical
algorithm. Data have been deposited into the Gene
Expression Omnibus repository (http://www.ncbi.nlm.nih.
gov/geo) under accession number GSE44056.
Illumina RNA-Seq
RNA sequencing was performed at the Australian
Genome Research Facility (Melbourne, VIC, Australia).
A cDNA library was prepared from 10 μg of total RNA
using the mRNA-Seq Sample Preparation Kit (Illumina,
San Diego, CA, USA) according to standard manufac-
turer protocol. Quality of the library was verified using a
DNA 1000 chip using the Agilent 2100 Bioanalyzer
(Agilent) and quantified by fluorimetry. Illumina tech-
nology allows both identification of the mRNAs present
in the total RNA preparations analyzed, and provides a
relative number of mRNA copies for these genes in each
of the different preparations. In brief, the library was
subjected to 100 bp single end read cycles of sequencing
on an Illumina Genome Analyzer IIx (Illumina) as
per manufacturer protocol. Cluster generation was per-
formed on a c-Bot (Illumina) with a single read cluster
generation kit. Refer to [34] for full methods and
bioanalysis. Details of the analysis of the output from the
high throughput RNA-Seq are published separately [34].
Briefly, reads were trimmed to remove ambiguous bases
from the start and segments with low quality scores
from the end. Trimmed reads were mapped with Bowtie
version 0.12.7 to the Ensembl rat genome, release 61,
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and reads that did not map uniquely were discarded.
The number of reads mapped to nuclear genes was de-
termined with HTSeq version 0.4.7p4, using the default
“union” counting option. Data have been deposited into
the Gene Expression Omnibus repository under acces-
sion code GSE44072.
Quantitative real-time PCR
RNA (1 μg) was spiked with 25 pg of bacterial AraB
RNA from E.coli (GE Healthcare Bio-Sciences Freiburg,
Germany), used as an external standard for normalization,
as the expression of conventionally used house-keeping
genes proved to be variable between developmental stages.
RNA was reverse transcribed using the iScript Reverse
Transcription Supermix (Bio-Rad, Hercules, CA, USA).
Protocols for qRT-PCR performed with the LightCycler
FastStart-DNA Master SYBR Green I kit in the LightCycler®
1.5 Instrument (Roche Diagnostics GmbH, Mannheim,
Germany), data analysis, and statistics have been described
previously [15]. The number of biological replicates used
was sufficient to assess a statistical significance for a
Log2FCad value of 1 with a statistical power averaging 95%
(alpha error level set at 0.05) for all genes whose level of ex-
pression was defined by a crossing-point lower than 32. All
primers were designed using NCBI Primer-BLAST and se-
lected to generate amplicons with a length of 100 to
200 bp. A list of primers, amplicon sizes and MgCl2-con-
centrations used for qRT-PCR is given in Additional file 1.
Data presentation
Adult choroid plexuses were used as reference sample
for all three techniques. On all graphs, data are
expressed as Log2-transformed fold changes (FC) of ex-
pression levels in developing versus adult choroid plexus
(Log2 FCad). Negative and positive values indicate lower
and higher expression in choroid plexuses of developing
animals than in choroid plexuses of adult rats, res-
pectively. Data are means of two (Affymetrix), three
(Illumina) or more (qRT-PCR) values, obtained from
different RNA preparations.
Genes detected with a fluorescent intensity value in
adult choroid plexus higher than 1000 on the Affymetrix
arrays were considered highly expressed and are in-
dicated in bold in the figures. Genes with a value be-
tween 100 and 200, i.e. close to background (mean value
of 60), or with a crossing point value above 30 by qRT-
PCR, were considered to be expressed at low level and
are indicated in parentheses. As a reference, the
transthyretin gene, which product is one of the most
abundant proteins synthesized by choroid plexus, was
the gene with the 100th highest level of expression in
adult on the array, with a fluorescent intensity value
of 13244, and had a crossing point of 12 in our amplifi-
cation conditions. The classification is only indicative, as
the hybridization efficacy may vary from one probe to
another.
Results and discussion
Combined analysis of gene expression data by Affymetrix
microarray, Illumina RNA-sequencing, and qRT-PCR
The expression level of selected genes was assessed in
E19, P2, and adult rat lateral ventricular choroid plexus
using Affymetrix microarrays, and in E15 and adult lat-
eral ventricular choroid plexus by Illumina RNA-Seq
analysis. Combining the two techniques enabled the in-
clusion of a larger number of genes in the study as some
of these genes were identified by either Affymetrix or
Illumina technology only. Some choroidal transcripts of
special relevance to possible brain protection, but not
represented on the arrays, were analyzed by qRT-PCR.
For each gene, the adult stage included in all methods of
analysis served as a reference to normalize the data set.
Individual developmental profiles were built from the
Log2 FCad mean values calculated at each stage. The
profiles are grouped and interpreted for families of genes
with similar functions.
To optimize the reliability of the data generated by
microarrays, mRNA samples were prepared from two
separate pools of choroid plexuses, each being collected
from several animals. The choroidal tissue was carefully
controlled with a stereomicroscope to verify the absence
of contaminating tissue. Performance of the amplifica-
tion/labeling reaction and of hybridization was assessed
by external spike-in controls (exogenous RNAs added to
the mRNAs samples before amplification, and biotin-
labeled cRNA added prior to hybridization). The perfect
alignment of signals detected for these spikes along the
line of identity on plots comparing duplicate microarrays
validates the technical reproducibility of the data (not
shown). The duplicate choroidal mRNA populations an-
alyzed for each stage were highly similar as the expres-
sion level of 99.4% of all genes detected at level above a
background of 100 fluorescence units as defined by
Affymetrix software differed by less than a factor of two
between samples (not shown). Finally, the expression
levels of the neuroprotective genes reported in this study
differed only by 12.4 ± 1.4% (mean ± SEM) between the
two matching samples.
The qRT-PCR and Illumina RNA-Seq methods have
some advantages over the microarray technology. Being
both based on the relative quantification of the number
of mRNA copies, they generate similar fold-changes
[35,36]. They offer a larger dynamic and linear range of
expression levels and are in theory more accurate for
quantifying gene expression. Owing to the absence of
standard curves compared with qRT-PCR, and the
higher background compared to RNA sequencing, the
microarray technology might yield fold changes with
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lower accuracy. We further tested the reliability of our
Affymetrix microarray data by comparing the E19-to-
adult fold changes obtained by this technique to those
calculated by qRT-PCR (n = 3 for E19, n = 4 for other
stages) for eighteen genes related to intercellular junc-
tions, transport and detoxification (Cldn1, Cldn3, Cldn5,
Cldn11, Cldn12, Cldn19, Ocln, Tjp1, Tjp2, Tjp3, Abcc4,
Abcg2, Slco1a4, Slco1a5, Slco1c1, Slc22a17, Slc22a8,
Ephx1). For all genes, both Log2 FCad values were of the
same sign, either positive or negative. Furthermore, the
average variation between the two Log2 FCad values
calculated for the 18 genes was low (31.7 ± 9%, mean ±
SEM). In the figures, only microarray data are presented
for these genes.
Altogether, these results provided a good indication
that Affymetrix data could be reliably combined with
qRT-PCR and Illumina RNA sequencing data, therefore
enabling a most comprehensive gene expression analysis
by reducing the number of false-negative genes associ-
ated with each of the techniques. Previous similar stud-
ies comparing Affymetrix microarrays and Illumina
RNA-Seq to analyze gene expression showed that the
two methods generate reasonably similar data, with
RNA sequencing identifying additional genes not repre-
sented in the microarrays [37,38].
Developmental profile of TJ-associated genes
The restriction of intercellular diffusion is a mandatory
prerequisite for effective and regulated transport across
cellular barriers. At both early embryonic (E15) and peri-
natal (E19 and P2) stages, a large number of TJ-
associated genes were expressed in choroid plexuses at a
level equal or higher than that measured at the adult
stage (Figure 2A and C). These genes included the highly
expressed cldn1 and cldn3. The expression of seven
other genes was lower in E15 rats than in the adult, in
particular that of cldn2 (Figure 2B and D). Of note, for
most of these TJ-associated genes, the FC absolute
values were largely smaller at E19 than E15, reflecting
the establishment of a mature, adult-like phenotype be-
fore birth. These results are congruent with our previous
data that showed an early formation of complex TJs be-
tween choroidal epithelial cells, and a remodeling of the
TJ protein composition around birth in rat [12,15]. An
in-depth analysis of the genes involved in the formation,
maintenance and regulation of choroidal tight junctions
during early brain development is reported in another
article [34].
Developmental profile of efflux transporters
In this analysis we define transporters involved in brain
protection as efflux transporters that accept drugs and
other xenobiotics for substrates and display a broad spe-
cificity. Within ABC transporters, the Abcb1a/b, Abcg2,
and Abcc genes meet these criteria, as they are respon-
sible for the efflux of numerous endo- and xenobiotics
and of glutathione-, glucurono-, and sulfo-conjugates
[8,39]. Several Slc subfamilies, which also limit the cere-
bral availability of numerous compounds, were selected
in the study. Slco transporters carry amphiphilic anionic
drugs and various glucurono-, sulfo-, and glutathione-
conjugates. Slc22 proteins transport a large range of
both small relatively hydrophilic organic anions and
organic cations including β-lactam antiobiotics, non-
steroidal anti-inflammatory drugs, and antiviral nucleo-
side reverse transcriptase inhibitors [18,19]. Dipeptide
transporters of the Slc15 subfamily and nucleoside trans-
porters belonging to both Slc28 and Slc29 subfamilies
were also incorporated in the study, as they transport a
number of antiviral and/or nucleoside-derived drugs in
addition to their typical endogenous substrates [18,40].
ABC transporters
Several multispecific efflux ABC transporters have been
located at the blood–brain interfaces where they limit
the entry of harmful toxins, but also of pharmacologic
agents such as anticancer drugs or antiretroviral prote-
ase inhibitors [16,17,39].
Abcc1 and Abcc4 transcripts were abundant in choroid
plexuses throughout development, and were moderately
enriched in the adult compared to earlier stages. In con-
trast, the four other Abcc genes were expressed at a
similar or higher level during development compared to
adult. In particular, Abcc9 transcripts were strikingly
enriched in earlier stages, with a 144-fold higher level in
E15 compared to adult (p < 0.001). Expression levels of
Abcb1b and Abcg2 were also higher at E15 and perinatal
stages (qRT-PCR: p < 0.05) than in adult, in which they
were apparently very low (Figure 3A).
These results indicate that the main Abc transporter
genes expressed in choroid plexus belong to the Abcc
subfamily. This is in accordance with a previous report
showing the expression of Abcc1, Abcc4, Abcc5, and to a
lesser extent Abcc3 in this tissue in adult rat [41]. It is
also in agreement with the expression of these genes in
both embryonic and adult mouse choroid plexuses [4].
Abcc1 protein was largely enriched in mouse, rat and
human choroid plexuses compared to other brain tis-
sues, as shown by immunohistochemistry and Western
Blot [16,25]. In vivo transport experiments using knock-
out mice pointed to the role of this carrier in limiting
the CSF concentration of drugs such as etoposide in the
CSF [16]. In mouse, Abcc4 protein was located in both
the luminal membrane of brain capillaries and the
basolateral membrane of the choroidal epithelium [17].
Microdialysis studies showed that this carrier strongly
restricts the passage of drugs such as topotecan from the
blood into the CSF [17]. The developmental patterns
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observed also corroborate previous data showing sub-
stantial expression levels of Abcc1 and Abcc4 in newborn
rat choroid plexus [23], and the developmental up-
regulation observed between E15 and adult for both
Abcc genes [24]. Despite the developmental regulation of
Abcc1 level of expression, Abcc1 protein level was
already as high in P2 rats as in adult and was also lo-
cated at the basolateral membrane of the choroid plexus
[25]. Overall, the Abcc developmental profiles suggest
that in addition to the main Abcc1, Abcc4 and other
Abcc transporters may have a crucial function as efflux
pumps during early brain development.
The low level of Abcb1 transcripts in adult rat choroid
plexus is in line with earlier findings that showed, using
Western blot analysis of adult rat and human tissues,
that Abcb1 protein was far less abundant in choroid
plexus by comparison to microvessels [25]. Similarly, the
low level of expression of Abcg2 that we report in adult
choroid plexus is accordant with the differential immu-
noreactivity of microvessels (highly positive) compared
to choroid plexuses (negative), observed for this trans-
porter in adult rat brain [24,42]. The higher expression
of both Abcb1 and Abcg2 from early embryonic to post-
natal stages (Figure 3A) suggests that these transporters
fulfill age-related functions at the choroid plexus. A
similar enrichment of Abcg2 transcripts in E15 com-
pared to adult was described in mouse choroid plexuses
[4], and Abcg2 immunoreactivity was detected in embry-
onic rat choroid plexus, but not in the adult tissue
[24,42]. The localization of the transporter at the
basolateral membrane of the choroidal epithelial cells in-
dicates that it could act as an efflux pump, similarly to
Abcc1 and Abcc4. The precise localization of Abcb1 and
other Abcc transporters identified in embryonic choroid
plexus remains to be determined in order to understand
the polarity of transport achieved by these proteins at
the blood-CSF barrier.
Slco transporters
Members of the Slco subfamily, referred to as organic anion
transporting polypeptides, mediate sodium-independent
transport of relatively large amphipathic substrates such as
taurocholate, thyroid hormones, leukotrienes, and various
drugs among which non-steroidal anti-inflammatory drugs,
the synthetic opioid peptide DPDPE, digoxin, or dexa-
methasone. They also transport conjugates of steroids,
drugs, and other xenobiotics [43].
Within this family, Slco1a5 and Slco1c1 were highly
expressed in rat choroid plexus (Figure 3B). They were
both enriched in the adult compared to prenatal stages
(RNA-Seq or qRT-PCR: p < 0.01). The expression level
of Slco1a5, low at E15, rapidly increased to approach
adult level by E19. Slco1c1 transcript level increased
more steadily between E15 and adult. Four additional
genes of this family, Slco1a4, Slco3a1, Slco2a1, and
Slco2b1 were identified in choroid plexus, and expressed
at equal or higher level in developing animals compared
to adults.
Slco1a5 is a highly expressed choroidal transporter
[18,41], which is located at the apical membrane of the
choroid plexus epithelium [18,41]. It appears to play a
major role in CSF-to-blood transport of organic anions
[44]. The already substantial expression of Slco1a5 at
E19 compared to E15 suggests that the functional activ-
ity of this transporter is critical during the perinatal
period. Slco1a4 protein has been previously detected in
adult choroid plexus [45] where it is located at the
basolateral membrane of choroidal epithelial cells [46].
Considering the partially overlapping substrate speci-
ficities of Slco1a5 and Slco1a4 [47], the polarized and
opposite distribution of these transporters at both mem-
brane domains of choroid plexus epithelial cells could be
important for vectorial transport of ligands out of the
CSF. Alternatively, the apical Slco1a5 protein may work
in concert with basolateral Abcc transporters to achieve
efficient CSF-to-blood efflux of organic anions.
Of note is the unexpected developmental regulation of
Slco1c1 at the choroid plexus. This carrier is a high affin-
ity transporter of thyroxine, a thyroid hormone import-
ant for multiple neurodevelopmental processes. Thyroid
hormone deficiency in the brain during the fetal and
neonatal period can cause mental retardation [48,49].
The low expression of choroidal Slco1c1 in the embry-
onic and perinatal stages suggests that other carriers are
active at the blood-CSF barrier to provide for cerebral
thyroxine requirements during early brain development
[50]. Slco3a1, whose expression is slightly enriched in
E19 and P2 compared to adult, and Slc16a10, expressed
in fetal and newborn choroid plexuses, are potential can-
didates. Two different splice variants of the SLCO3A1
protein have been located at the apical and basolateral
membranes of the human choroidal epithelium, and they
both mediate thyroxine uptake in transfected cells and
injected oocytes [51]. Slc16a10 is also an influx trans-
porter for T3 and T4. It was recently identified in mouse
embryo choroid plexus at a substantially (67-fold) higher
level than in the adult [4]. Another likely candidate is
transthyretin, whose synthesis in the brain is restricted
to choroid plexus. The transthyretin gene is highly
expressed throughout development in rat choroid plexus
([52] and data not shown), and this thyroxin carrier was
shown to be important and necessary for various aspects
of normal brain development [53].
Slc22 transporters
Members of the Slc22 subfamily are classified as organic
anion transporters, organic cation transporters, and
organic cation/carnitine transporters. Organic anion
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transporters are anion exchangers, and accept various
toxins and drugs as substrates, i.e. antineoplastics, anti-
hypertensives, non-steroidal anti-inflammatory drugs,
and ß-lactam antibiotics, such as benzylpenicillin [54].
Organic cation transporters function as membrane
potential-dependent uniporters that mediate the facili-
tated diffusion of endogenous amines such as dopamine,
or therapeutic drugs such as morphine and antihista-
mines. Organic cation/carnitine transporters carry car-
nitine with variable affinities. Two members of this
subfamily, octn1 and octn2, also accept different cationic
xenobiotics including drugs as substrates [55].
Slc22a5, Slc22a8, and Slc22a17 were highly expressed
in rat choroid plexus from E15 onwards. Seven add-
itional organic cation and anion transporter genes,
Slc22a2, Slc22a4, Slc22a6, Slc22a7, Slc22a12, Slc22a15,
and Slc22a25 were found expressed in the choroidal tis-
sue (Figure 3C). Transcripts were enriched in early em-
bryos for four of these genes, and enriched in adult for
four others. It should be noted that at E19, the expres-
sion levels of all ten Slc22 genes have almost reached
adult levels. To the exception of Slc22a12, all Log2 FCad
absolute values at E19 were equal or lower than 2. Log2
FCad values calculated at E15 were much more variable,
ranging between −7.16 for Slc22a8, reflecting a 143-fold
enrichment in adult, and 3.79 for Slc22a6, corresponding
to a 13.8-fold enrichment in E15.
Our findings are in accordance with a previous study
showing high constitutive mRNA levels for Slc22a5 and
Slc22a8 in adult rat choroid plexus in comparison to
other Slc22 transporters [41]. The Slc22a8 protein has
been located at the apical membrane of the choroidal
epithelium in rat [19,56]. Slc22a6 displayed the same cel-
lular distribution when expressed as a fluorescent pro-
tein in adult rat choroid plexus tissue explants [19,56].
Inhibition experiments in choroidal cell monolayers
pointed to apical Slc22 carriers, likely Slc22a8, as medi-
ating the active efflux of antiviral nucleoside analogs
across the blood-CSF barrier [57]. Slc22a6 and Slc22a8
transporters share a large number of exogenous sub-
strates [58]. Our present data on their respective inverse
profile of expression during development suggest that
they sequentially contribute to organic anion clearance
from the CSF. The switch from 22a6 to 22a8 in the em-
bryo may reflect a need to adapt to changes in endogen-
ous substrates at that period.
The expression of Slc22a5 in choroid plexus was high
and steady in the developing brain. This organic cation
Figure 2 Developmental profiles of tight junction-associated genes in rat choroid plexus. Analysis was performed on lateral ventricle
choroid plexus at four developmental stages. Affymetrix and Illumina RNA-Seq techniques were combined and data expressed as Log2 values of
fold change relative to adult (Log2 FCad). For selective genes that were absent in Affymetrix chips, qRT-PCR was performed. Strongly expressed
genes are indicated in bold. (A and B) show gene expression profiles for claudins with decreasing and increasing expression during
development, respectively. (C and D) show gene expression profiles for selected other TJ-associated protein transcripts. Abbreviations: E15,
embryonic day 15; E19, embryonic day 19; P2, postnatal day 2; ad, adult. Correspondences between gene symbols, common names, and
accession numbers are listed in Table 1.
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transporter will mediate toxic efflux from the CSF if
the site of cellular uptake is apical. Its membrane
localization is presently unknown. Because Slc22a5
transports carnitine with the highest affinity among
Slc22 proteins, it could participate in the control of car-
nitine homeostasis in the developing brain. Although
carnitine is a necessary cofactor of mitochondrial β-
oxidation that generates energy from fatty acids, this
function is not essential for the developing brain, be-
cause peripheral ketone bodies, rather than fatty acids
themselves, fuel the brain in suckling animals [59].
Carnitine may function as an antioxidant [60] or a pro-
moting and modulatory agent for synaptic neurotrans-
mission, notably cholinergic transmission [61]. The high
and steady expression of Slc22a17 throughout develop-
ment is noteworthy. This carrier is a cell surface recep-
tor for the siderophore-binding protein 24p3, also
known as lipocalin-2. In the brain the highest Slc22a17
transcript levels are found in choroid plexus [62]. Mur-
ine Slc22a17 protein, when expressed in HeLa cells,
binds both the iron-free and Fe-containing 24p3. It
enables their internalization by endocytosis and leads to
either apoptosis or increase in intracellular iron-content.
Through its binding to 24p3, Slc22a17 may influence
infectious/inflammatory processes at the blood-CSF
barrier. As a siderophore-binding protein, 24p3 has po-
tential bacteriostatic properties. It also forms a complex
with the matrix metalloproteinase MMP-9 [63]. Both
24p3 and MMP9 are highly up-regulated in choroid
plexus under inflammatory stimuli [64,65]. The relation-
ship between Slc22a17, 24p3 and MMP9 at the choroid
plexus, as well as the relevance of the high Slc22a17 ex-
pression during development needs further investigations.
Slc15, Slc28 and Slc29 transporters
The Slc15 subfamily comprises proton-coupled oligo-
peptide transporters [66]. Among these, Slc15a2 trans-
ports peptidomimetic drugs such as the antiviral agent
aciclovir or the β-lactam antibiotic cefadroxil. Slc15a2
protein was shown by immunocytochemistry to distrib-
ute at the apical and subapical domain of rat choroid
plexus epithelial cells in culture [67]. Accordingly,
Figure 3 Developmental profiles of Abc and Slc efflux transporters. (A) shows gene expression profiles for Abc genes. Abcc3 was
expressed at E19 and at P2, but was not detected in adult by Affymetrix analysis. (B) shows gene expression profiles for the Slco genes. (C) shows
gene expression profiles for the Slc22 genes. Slc22a4 displayed the same Log2 FCad as Slc22a7 at E19, P2 and adult, thus profiles are overlapping.
Slc22a12 was detected at E15, but not in adult by Illumina RNA-Seq method. (D) shows gene expression profiles for Slc15, Slc28, and Slc29 genes.
Strongly expressed genes are indicated in bold. Genes indicated in parentheses have an apparent very low expression level in adult choroid
plexus. Abbreviations, data analysis, and data expression as in Figure 2.
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studies using knock-out mice indicated that this trans-
porter removes peptide substrates from CSF into the
choroidal tissue [66]. The present analysis showed high
levels of expression for Slc15a2 that remained relatively
unchanged during development (Figure 3D). These data
support a protective role for this transporter in the
developing brain toward neuropeptides in excess or
peptidomimetic drugs. Slc15a3 and Slc15a4, which trans-
port free histidine and endogenous di- or tripeptides,
followed a developmental expression pattern similar to
Slc15a2 (data not shown). Their membrane localization
and functions are currently unknown.
Slc28 and Slc29 transporters play critical roles in cellu-
lar uptake and release of nucleosides that are precursors
for nucleotide biosynthesis. Even though brain penetra-
tion of nucleoside reverse transcriptase inhibitors used
for AIDS treatment is not mediated by choroidal nucleo-
side transporters [57], these carriers can transport other
anti-viral drugs and the anti-cancer drug gemcitabin
[40,68]. Two concentrative Na+-coupled nucleoside
transporters Slc28a2 and Slc28a3, and four equilibrative
nucleoside transporters, Slc29a1 to Slc29a4 were identi-
fied in choroid plexus of E15 rats (Figure 3D). Most of
these nucleoside transporters were expressed at levels
close to adult levels from E15 onwards. Only Slc28a3
and Slc29a4 had lower transcript levels at E15 (p <
0.001). Functional transport and inhibition studies indi-
cate a polarized localization of concentrative nucleoside
transporters on the apical membrane, and equilibrative
transporters on both the apical and basolateral mem-
brane domains [69]. This subcellular distribution would
imply that the concentrative transporters, possibly in
conjunction with basolateral equilibrative transporters,
fulfill neuroprotective functions by effluxing substrates
from CSF rather than contributing to nucleoside entry
into brain. This protective mechanism should be effi-
cient already in the developing brain.
Developmental profile of drug-metabolizing and
antioxidant enzymes
Drug metabolizing enzymes include functionalization
(phase I) enzymes that add or transform a functional
group on lipophilic compounds. Resulting metabolites
are usually less active and more polar. Cytochrome
P450s (Cyp), in particular members of the Cyp1-3 fam-
ilies, flavin-containing monooxygenases (Fmo), and ep-
oxide hydrolases play an important role in phase I of drug
metabolism, by inactivating exogenous compounds includ-
ing various drugs, pesticides, dietary-derived compounds
and carcinogenic molecules. Drug metabolizing enzymes
also include conjugation (phase II) enzymes that add a
hydrophilic moiety such as glucuronic acid, sulfate, or
glutathione to the parent drug or the phase I metabolite.
Drug metabolizing enzymes of both phases have been asso-
ciated with blood–brain interfaces [21,70].
Phase I drug metabolizing enzymes
Among the more than 88 Cyps genes identified so far
in the rat species (http://drnelson.uthsc.edu/rat.master.
table.html), only four of them were detected in the lat-
eral ventricle choroid plexus (Figure 4A). Cyp2d4 tran-
scripts were enriched at the adult stage, while Cyp1b1
transcripts were enriched in embryos and perinatal
stages. Cyp2j4 and Cyp2u1 expression did not change
throughout development. Expression of microsomal ep-
oxide hydrolase 1 (Ephx1) was high and steady in chor-
oid plexus from E19 onwards, and only moderately
lower (6-fold, p < 0.001) at E15. Ephx2 transcripts, cod-
ing for the soluble form of epoxide hydrolase, were more
abundant in choroid plexus from developing animals
compared to adults (Figure 4A). All Fmo genes (Fmo1
to −5) were expressed in choroid plexus from developing
animals at levels close to adult levels, except for Fmo3,
which was lower at P2 and E19 and undetectable at E15
(Figure 4B).
The present data suggest that Cyps play a marginal
role in detoxification at the choroid plexus. This is in
line with the low Cyp activities reported previously for
choroidal tissue [70], and with the lack of Cyp1a1 activ-
ity in choroid plexus, the protein being detected only
after inductive treatment and only in choroidal vessels
[71,72]. Of note, Cyp1b1, known as the main Cyp iso-
form expressed at the blood–brain barrier in both rat
and human [73,74], may have a specific detoxification
function at the choroid plexus in early development, as
its expression is highest in the pre- and postnatal period.
In contrast to Cyps, both Fmos and epoxide hydrolases
appear to play significant detoxification roles at the
blood-CSF barrier. The high level of expression of Ephx1
in choroid plexus is in line with the high mEphx1 activ-
ity measured in the rat tissue [70] and with the strong
immunoreactivity of the mouse choroidal epithelium
[75]. Ephx1 is well expressed throughout development,
pointing to an efficient enzymatic protection towards
carcinogenic epoxides and epoxide drug-intermediates
from the embryonic period onwards. Ephx2 more
specifically metabolizes lipid-derived epoxides, such as
epoxyeicosatrienoic acids. Its age-dependent expression
profile suggests a function in modulating lipid signaling
during development.
Fmo1 and Fmo3, whose transcripts were both detected
in choroid plexus, are considered as the most important
members in the Fmo family with regard to detoxication
of foreign compounds [76]. Fmo1 mRNA was previously
detected in mouse choroid plexus by in situ hybridization
[76]. The developmental profiles we observed for Fmo
genes suggest that Fmo1-dependent biotransformation
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reactions support important choroidal detoxification path-
ways in the developing brain, which have never been ex-
plored. The significance of Fmo2 transcripts encoding a
truncated non-functional protein [76], and of Fmo4 and
Fmo5 which were expressed at continuous but low level
during development remains elusive in the context of
detoxification.
Phase II drug metabolizing enzymes
Phase II of drug metabolism is catalyzed mainly by UDP-
glucuronosyltransferases (Ugt), sulfotransferases (Sult), and
glutathione-S-transferases (Gst). Similar to efflux trans-
porters, the three enzyme families are multigenic families,
composed of multiple isoforms with differential substrate
specificities. This explains the broad substrate specificity of
the overall detoxification process [21].
Among detoxifying Ugts, the highly homologous genes
of the Ugt1a subfamily could not be distinguished by the
microarray probes. Transcripts of these genes were
highly and steadily present from E19 to adult (Figure 4C).
Their level of expression was lower at E15. This is in
agreement with enzymatic data showing that planar
molecules, which are typical substrates of Ugt1a en-
zymes, are efficiently conjugated by choroid plexus epi-
thelial cells both in adult and newborn rat [22,70]. The
Ugt1a1 isoform plays an important physiological role in
the hepatic clearance of bilirubin in addition to xenobi-
otics. Conjugation of bilirubin at the blood-CSF barrier
could represent an efficient mechanism to prevent the cere-
bral accumulation of bilirubin in hyperbilirubinemia [77].
Sult1a1 displayed a similar profile of expression, its
transcripts being enriched from E19 to adult, compared
to E15. In line with this apparent high level of choroidal
expression, Sult1a1-dependent enzymatic activity mea-
sured in various human brain regions from fetuses of
15–20 weeks of gestation was the highest in choroid
plexus [27]. Sult1a1 is also responsible for the inactiva-
tion of thyroid hormones. In addition to xenobiotic con-
jugation, choroidal Sult1a1 could regulate the levels of
these hormones critical for brain development.
Gsts are homo- or heterodimeric enzymes divided into
three families, the cytosolic, microsomal and mitochon-
drial transferases. Within cytosolic Gsts, the alpha
(Gsta), mu (Gstm), and pi (Gstp) classes are mainly in-
volved in drug metabolism and detoxification pathways
[30]. Some microsomal Gsts (Mgst) were also examined
in this study. Although their best known functions are
related to the biotransformation of arachidonic acid me-
tabolites, these isoforms are also active in detoxification
[30,78]. Five out of seven detoxifying isoforms, Gsta3,
Gsta4, Gstm1, Gstm5, and Gstp1, were highly expressed
at the choroid plexus (Figure 4D). All mu isoforms, as
well as Gstp1 were expressed in choroid plexus of devel-
oping animals at similar or higher levels compared to
adult. By contrast, transcripts of alpha Gsts were enriched
in the adult (5- and 7-fold for Gsta3 and Gsta4 respectively)
compared to E15. Mgst1, highly expressed in choroid
plexus, showed a clear developmental up-regulation from
E15 to adult, in contrast to Mgst3 whose mRNA level was
highest at E15 (Figure 4E). The diversity of Gst genes that
we found expressed in choroid plexus is in accordance with
the previous immunodetection of all alpha, mu and pi Gst
classes in the adult rat choroidal epithelium [79-81]. The
overall high levels of Gst transcripts observed during the
perinatal period is in line with earlier studies showing Gst-
positive cells in rat choroid plexus at embryonic day 16 [82]
and with the presence of Gst pi in human fetal choroid
plexus [83]. This transcriptional regulation parallels our
previous enzymatic data showing that in both rat and hu-
man the choroidal conjugation of GSH with 1-chloro-2,4-
dinitrobenzene, a substrate for multiple GSTs, was higher
in fetus and newborn than in adult [22,23].
The rate of glutahione synthesis is in part determined
by the activity of glutamate-cysteine ligase, which is
composed of a catalytic subunit (Gclc) and a modulatory
subunit (Gclm). These two genes, as well as the glutathi-
one synthase gene (Gss) were expressed in choroid
plexus from E15 onwards (Figure 4F). Transcripts levels
in perinatal stages were equal or slightly higher to those
in adult. These profiles suggest that the large capacity of
the choroidal tissue to synthesize glutathione described
in adults [84] is already acquired in embryos.
Both Mgst1, previously localized in epithelial cells of rat
choroid plexuses [85], and Mgst3 have been described to
have a peroxidase activity in addition to their glutathione-
S-transferase activity [30]. In vitro experiments performed
in MCF-7 breast carcinoma cells suggested that Mgst1 pro-
tects the cells against damages induced by cytostatic drugs
or against SiO2 nanoparticle-induced oxidative stress and
cytotoxicity [86]. Such antioxidant protection would be
provided at the choroid plexus during development, by
Mgst3 in earlier stages, then by Mgst1. These enzymes
could reinforce the overall large antioxidant capacity of
choroid plexus, which relies on various other enzymes
present in this tissue (see below).
Antioxidant enzymes
Cells forming the blood-CSF barrier are exposed to oxi-
dative stress of various origins. First, they face blood-
borne pro-oxidant compounds. They also have an overall
high mitochondrial activity, which is a substantial local
source of oxygen-derived species. In addition, these cells
are exposed to the reactive and potentially deleterious
intermediate metabolites that can form as a drawback
of phase I oxidative and reductive metabolism and of
selected phase II reactions. Choroidal cells possess an
extensive enzymatic machinery to inactivate all these re-
active molecules. It includes superoxide dismutases
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(Sod), which inactivate superoxide anions, catalase (Cat),
which cleaves hydrogen peroxide, and glutathione
peroxidases (Gpx), which metabolize a large spectrum of
peroxide species. Some isoforms of the latter enzymes
require glutathione in their catalytic cycle, and thus
function in conjunction with glutathione reductase
(Gsr), which regenerates the reduced form of the thiol-
containing molecule (reviewed in [87]).
Five out of eight Gpx genes identified in mammals
(Gpx1, -3, -4, -7, and −8) and Gsr were detected in
choroid plexuses (Figure 5A). All were expressed at
similar or higher levels during the perinatal period com-
pared to adult. At E15, Log2Fcad absolute values were
lower than 2, indicating only limited variation at this
early embryonic stage. Gpx1 and Gpx4 were expressed
at high levels at all stages. Gpx1 is mainly devoted to the
metabolism of hydrogen peroxide when produced in ex-
cess, as occurring in infections, while Gpx4 specifically
inactivates membrane-integrated hydroperoxy lipids. It
thereby counteracts the activity of lipoxygenases, and
Figure 4 Developmental profiles of drug metabolizing enzymes. (A) shows gene expression profiles for different cytochrome P450 enzymes
and epoxide hydrolases in the lateral ventricle choroid plexus. Cyp2u1 and Ephx1 display similar Log2 FCad during development, thus the
developmental profile overlap on the graph. No expression for Cyp2u1 was detected at E15. (B) shows gene expression profiles for flavin-
dependent monoxygenase. Fmo3 was undetectable at E15. (C) shows gene expression profiles for UDP glucuronosyltransferases and
sulfotransferases. Ugt2a1 was detected in adult, but not at E15. (D) shows gene expression profiles for soluble glutathione-S-transferases, and (E)
for microsomal glutathione-S-transferases. (F) shows expression profiles for genes involved in GSH synthesis and metabolism. MI, multiple
isoforms. Other abbreviations, data analysis, and data expression as in Figures 2 and 3.
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can modulate inflammatory responses [87]. Very high
Gpx activities have been measured in rat choroid plex-
uses isolated from adults [88]. It is expected from our
data that these enzymes are already functional at earlier
times and therefore contribute to protect the developing
brain against oxidative and inflammatory insults. The
soluble Cu/Zn superoxide dismutase genes Sod1 and
Sod3, as well as the cat gene were also highly expressed
in choroid plexus both during the perinatal period and
in adult (Figure 5B). Variations in expression of Sod
genes were more heterogeneous in choroid plexuses in
E15 animals than in subsequent developmental stages. A
strong immunoreactivity for catalase was previously
detected in rat choroid plexus as early as at E14.5 [89].
Mammalian cells display several other means of
protection against reactive species, including the heme
oxygenase (Hmox) pathway. Hmox proteins catalyse
the degradation of heme, resulting in the formation of
biliverdin, which in turn can be converted via biliver-
din reductases (Bvr) into bilirubin. Intracellular un-
conjugated bilirubin acts as antioxidant, and the
biliverdin/bilirubin redox cycle is considered as an im-
portant constituent of the cellular antioxidant defense
system acting mainly towards lipophilic reactive spe-
cies [77]. Moderate hyperbilirubinemia was found
neuroprotective against focal ischemia to which neo-
nates are especially susceptible [90]. Both stress-
inducible Hmox1 and constitutive Hmox2 genes, as
well as the Bvra and Bvrb genes were expressed in
choroid plexus (Figure 5C). For all four genes, tran-
scripts were detected at similar or slightly higher levels
during development than in adults (log2 FCad values
between −0.92 to 2.44). In line with our data, immuno-
reactivity of Hmox-2 usually considered as a neuronal
isoform, has been reported in choroid plexuses of adult
rats [91]. The steady expression of Hmox2 and the con-
current enriched levels of Hmox1 transcripts in embry-
onic stages represent a potent heme catabolic system
able to generate biliverdin, not only in normal develop-
mental conditions, but also in response to perinatal in-
sults. In contrast to the liver, in which bvra and bvrb
showed opposite age-dependent profiles of expression
[92], both genes were expressed at similar levels in
choroid plexuses from E19 to the adult stage. Thus the
bilirubin/biliverdin antioxidant redox cycle is likely to
be efficient in choroidal cells throughout development.
Transcription factors involved in the regulation of
detoxifying genes
Ligand and non-ligand activated transcription factors
involved in the coordinated regulation of drug-
metabolizing enzymes and transporters were incorpo-
rated in our study. They include the aryl hydrocarbon
receptor (Ahr), the pregnane X receptor (Nr1i2), the
Figure 5 Developmental profiles of other antioxidant enzymes. (A)
shows gene expression profiles for different glutathione peroxidases and
glutathione reductase, (B) shows gene expression profiles for superoxide
dismutases and for catalase, and (C) for heme oxygenases and biliverdin
reductases. Abbreviations, data analysis, and data expression as in
Figures 2 and 3.
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constitutive androstane/activated receptor (Nr1i3), the
peroxisome proliferator-activated receptor α (Ppara),
the glucocorticoid receptor (Nr3c1), and the CCAAT/
enhancer binding protein beta (Cebpb) reviewed in
[29], and [30]. Ahr dimerizes with the Ahr nuclear
translocator (Arnt, also known as Hif1b). Nr1i2, Nr1i3
and Ppara heterodimerize with the retinoid X receptor
α (Rxra). The tumor protein p53 (Tp53) was added to
the study as it was shown to directly mediate the tran-
scriptional induction of Abcb1 induced by genotoxic
compounds [93]. The oxidative stress sensor nuclear
factor erythroid 2-related factor 2 (Nfe2l2) and the
hypoxia-inducible factor 1 alpha (Hif1a), all transcrip-
tion factors involved in inductive processes mediated
by redox imbalance and whose activation leads to the
induction of detoxifying genes, are also reported. Four
of these genes, Rxra, Nfe2l2, Hif1a, and Nr3c1 were
expressed at high levels in choroid plexuses. Apart
from Nr1i2, whose expression was clearly upregulated
from E15 to adult stage (p < 0.001), the choroidal ex-
pression of all transcription factors was remarkably
steady throughout development (Figure 6). Absolute
log2 FCad values determined at E19 were between 0
and 0.9.
Induction of choroidal drug metabolizing enzymes in
choroid plexuses has been demonstrated only in adult
rats, following treatment with polycyclic aromatic hydro-
carbons, indicating that the AhR/Arnt-dependent path-
way is functional at the blood-CSF barrier [72,94]. If
functionality proves true for all factors throughout de-
velopment, the panel of transcription factors that are
expressed in choroid plexus suggests that following ex-
posure to a large range of chemical xenobiotics the ac-
tivity of drug metabolizing enzymes and transporters in
the blood-CSF barrier can be induced in adult as well as
in developing animals. Of note, the lower choroidal
Nr1i2 expression at E15 could be compensated by Nr1i3
transcripts, as these two transcription factors regulate a
number of common genes well expressed at the choroid
plexus, such as Ugt1a, Abcc and cytosolic Gsts [95].
Similarly, the steady expression of Nfe2l2, Hif1a, and
Arnt suggests that the neuroprotective functions of the
blood-CSF barrier can be modulated in response to hyp-
oxia and oxidative stress, whether occurring at early de-
velopmental age or in adult.
Developmental profile of enzymes forming a barrier to
neurotransmitters
A function of enzymatic barrier to monoamine neuro-
transmitters, that involves three enzymes, has been
ascribed to the choroidal epithelium [96]. The Dopa-
decarboxylase (Ddc) catalyzes the decarboxylation of
L-3,4-dihydroxyphenylalanine (L-Dopa) to dopamine, L-
5-hydroxytryptophan to serotonin, and L-tryptophan to
tryptamine. Monoamine oxidases (Mao) in turn
metabolize and degrade the monoamine neurotransmit-
ters dopamine, serotonin, and adrenalin. Catechol-O-
methyltransferase (Comt) catalyzes the O-methylation of
catecholamine neurotransmitters and catechol hor-
mones, leading to their inactivation. It also shortens the
biological half-lives of certain neuroactive drugs, like L-
Dopa, alpha-methyl Dopa, and isoproterenol [97]. Chor-
oidal Ddc expression was 4- to 5.5-fold higher in the
choroid plexus of developing animals as compared to
adult, while levels of Maoa, Maob, and Comt transcripts
varied very little between E15 and adult (Figure 7).
These data suggest that a choroidal enzymatic barrier to-
wards neurotransmitters is already established before
birth. If functional, as observed in adult [96], it could
represent a protective mechanism preventing blood-
borne monoamines from interfering with central
neurotransmission.
General comments
The combination of Affymetrix microarrays, RNA-Seq
and qRT-PCR has enabled a comprehensive analysis
of expression of choroid plexus genes involved in
neuroprotection from embryonic through postnatal de-
velopment compared with the adult. By their nature,
microarrays are not comprehensive, but the additional
use of RNA-Seq and qRT-PCR allowed the detection
and quantification of genes not represented in the
microarray. On the other hand some genes detected in
the Affymetrix arrays were below or close to threshold
in RNA-Seq. The quantitative estimates of changes in
expression level of individual genes are more secure, be-
cause of the use of three independent methods.
Figure 6 Developmental profiles of transcription factors
involved in regulation of detoxifying genes. Gene expression
profiles for transcription factors that regulate drug-metabolizing
enzymes and efflux transporters, and for their co-regulators are
shown. Abbreviations, data analysis, and data expression as in
Figure 2.
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The choroidal tissue microdissected from brain is
predominantly constituted by the choroidal epithelial
layer that forms the blood-CSF barrier, it also contains
in smaller numbers fibroblasts and some myeloid cells
forming the stromal core of the choroid plexus, and
endothelial cells forming the choroidal vessels. Our
study does not discriminate between these different cell
types. However, apart from Cldn5 and Cyp1a1 which
are localized in choroidal vessels [15,71], all other
neuroprotective gene products for which immunohisto-
chemical or functional analyses have been performed at
the level of the choroid plexus have been identified in
the choroidal epithelium. These include Cldn1, Cldn2,
Cldn3, Cldn9, Cldn19, Abcc1, Abcc4, Slco1a4, Slco1a5,
Slc22a6, Slc22a8, Slc15a2, concentrative and equilibrative
nucleoside transporters, Ephx1, Ugt1a, several cytosolic and
membrane-bound Gsts, cat, and enzymes bearing a barrier
function to neurotransmitters [17-19,22,23,25,46,56,57,
67,69,75,80,85,89,96]. The present gene expression analysis
therefore supports the concept that the blood-CSF barrier
possesses an efficient neuroprotective machinery during the
pre- and postnatal stages of development. This is reflected
by the overall limited variation in the choroidal expression
of efflux transporters and metabolizing/antioxidant en-
zymes between E19, P2 and adult animals (Table 2). Only a
limited number of genes displayed a large age-dependent
up or down regulation within this timeframe. The 16-fold
higher transcript levels for Abcc9 and Slco2a1 detected at
E19 compared to adult likely reflect differences between
the perinatal and adult functions of the blood-CSF barrier.
These specificities remain to be investigated. The variation
in gene expression relative to adult levels is more pro-
nounced at E15 than at perinatal stages of development
(Table 2). Thirty percent of the neuroprotective genes ana-
lyzed in the present work were expressed at levels at least
4-fold lower at E15 compared to E19, reflecting some de-
gree of maturation of the functions associated with these
genes between early embryonic and late fetal stages. By
contrast, transcript levels were 4-fold higher or more in
E15 compared to E19 for only ten percent of the genes.
Given the growing evidence for the important role of chor-
oid plexus in early stages of brain development [4,98] these
particular choroidal transporters and enzymes may be in-
volved in brain development processes rather than in
neuroprotection per se.
Conclusions
The present data provide an overview of the multiple
enzymatic and transport systems expressed in choroid
plexus, which in conjunction with the epithelial tight
junctional complexes, contribute to the protective bar-
rier functions of the blood-CSF interface. However, it re-
mains to be confirmed by in vivo testing with drugs and
other xenobiotics if these systems are as functionally ef-
ficient in the developing brain as in the adult. Further
characterization of these proteins to determine their
localization and efficiency during development will en-
able more reliable risk assessment for drugs used to treat
perinatal diseases. Evidence for the choroidal expression
of various transcription factors involved in the induction
of neuroprotective genes opens new pharmacological
perspectives to improve neuroprotection at the inter-
faces between the blood and the central nervous system
in the context of both perinatal injuries and environ-
mental toxicity.
Figure 7 Developmental profiles of enzymes forming a barrier
to neurotransmitters. Gene expression profiles for monoamine
oxidases, dopa decarboxylase and catechol-O-methyltransferase
are shown. Abbreviations, data analysis, and data expression as in
Figure 2.
Table 2 Average amplitude of fold changes in
neuroprotective gene expression levels in E15, E19 and
P2 animals relative to adults in the choroid plexus
TJ proteins Transporters Enzymes
E15 5.9 ± 1.4 23.5 ± 9.2 5.1 ± 1.1
E19 2.5 ± 0.6 3.6 ± 0.9 2.1 ± 0.2
P2 1.9 ± 0.3 3.2 ± 0.7 1.9 ± 0.2
E15 vs. E19 * * **
E15 vs. P2 ** ** ***
E19 vs. P2 ns ns ns
Data are expressed as mean ± SEM of trend-independent FC calculated back
from Log2FCad “absolute” values for all the genes (but three), analyzed in this
study and illustrated in Figures 2, 3, 4, 5, 7. Slc22a12, Fmo3 and Ugt2a1 were
excluded because FCad values at E15 could not be calculated (see figure
legends). “Absolute” values of Log2FCad correspond to the value reported in
the different figures, except that negative signs were removed. This table thus
illustrates the FC amplitude independently of the variation trend, whether
expression levels are higher or lower in earlier stages compared to the adult.
*, **, ***Statistical differences between developmental stages, analyzed by
Kruskal-Wallis followed by Dunns multiple comparison test, p < 0.05, 0.01,
0.001, respectively. ns: not statistically different.
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Endnotes
a Gene official symbols (in italic), as defined on the
NCBI website, other common gene or protein names,
and accession numbers (NM; number mRNA) for all
genes analyzed in this study are listed in Table 1.
Symbols referring to human genes or proteins are
written in capital letters.
Additional file
Additional file 1: List of primers, amplicon sizes and MgCl2-
concentrations used for qRT-PCR.
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